BRPI0508556A - moduladores de canal iÈnico - Google Patents
moduladores de canal iÈnicoInfo
- Publication number
- BRPI0508556A BRPI0508556A BRPI0508556-0A BRPI0508556A BRPI0508556A BR PI0508556 A BRPI0508556 A BR PI0508556A BR PI0508556 A BRPI0508556 A BR PI0508556A BR PI0508556 A BRPI0508556 A BR PI0508556A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- channel modulators
- single channel
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000862 Ion Channels Proteins 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55137104P | 2004-03-08 | 2004-03-08 | |
| PCT/US2005/007902 WO2005086895A2 (en) | 2004-03-08 | 2005-03-07 | Ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0508556A true BRPI0508556A (pt) | 2007-08-07 |
Family
ID=34976220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0508556-0A BRPI0508556A (pt) | 2004-03-08 | 2005-03-07 | moduladores de canal iÈnico |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7368467B2 (https=) |
| EP (1) | EP1722783A4 (https=) |
| JP (1) | JP2007527913A (https=) |
| CN (1) | CN1946397A (https=) |
| AU (1) | AU2005221131A1 (https=) |
| BR (1) | BRPI0508556A (https=) |
| CA (1) | CA2557648A1 (https=) |
| WO (1) | WO2005086895A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1723117A4 (en) * | 2004-03-08 | 2009-12-02 | Wyeth Corp | ION CHANNEL MODULATORS |
| CA2558214A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| JP2007527919A (ja) * | 2004-03-08 | 2007-10-04 | ワイス | イオンチャンネルモジュレーター |
| US20070208064A1 (en) * | 2004-03-08 | 2007-09-06 | Wyeth | Ion channel modulators |
| US8916550B2 (en) * | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| EP1888575A2 (en) * | 2005-05-09 | 2008-02-20 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
| US7893260B2 (en) * | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| EP1939181A1 (en) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| EP3115045B1 (de) * | 2008-08-26 | 2020-08-12 | Basf Se | Nachweis und verwendung niedermolekularer modulatoren des kälte-menthol-rezeptors trpm8 |
| EA201100441A1 (ru) * | 2008-09-04 | 2011-10-31 | Ардеа Биосайнсиз, Инк. | Соединения для коррекции уровня мочевой кислоты и способы их применения |
| WO2010101724A1 (en) * | 2009-03-04 | 2010-09-10 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as modulators of faah and as faah imaging agents |
| WO2013054338A1 (en) * | 2011-07-06 | 2013-04-18 | Cadila Healthcare Limited | 2-thio-imidazole derivatives as tgr5 modulators |
| WO2013102929A1 (en) * | 2011-12-26 | 2013-07-11 | Cadila Healthcare Limited | Novel compounds for treatment of diabetes, obesity or related disorders |
| US20140235585A1 (en) * | 2013-02-20 | 2014-08-21 | Allergan, Inc. | Substituted diaryl derivatives as sphingosine receptor modulators |
| CA2965873C (en) * | 2014-10-29 | 2023-02-21 | Apoglyx Ab | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-n-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes |
| EP4096661B1 (en) | 2020-01-29 | 2025-04-02 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| EP4377297A4 (en) * | 2021-07-30 | 2025-05-28 | The Regents of the University of California | Compounds for modulating epithelial 15-(s)-lipoxygenase-2 and methods of use for same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734421A (en) * | 1986-10-29 | 1988-03-29 | Merck & Co., Inc. | Anti-inflammatory substituted 2-benzyl-mercapto-imidazole and pyrimidine derivatives compositions and method of use therefor |
| EP0994858A1 (en) * | 1997-06-30 | 2000-04-26 | Ortho-McNeil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US20030199523A1 (en) * | 2002-02-28 | 2003-10-23 | Snutch Terrance P. | Heterocyclic calcium in channel blockers |
| EP1723117A4 (en) * | 2004-03-08 | 2009-12-02 | Wyeth Corp | ION CHANNEL MODULATORS |
-
2005
- 2005-03-07 US US11/075,629 patent/US7368467B2/en not_active Expired - Fee Related
- 2005-03-07 WO PCT/US2005/007902 patent/WO2005086895A2/en not_active Ceased
- 2005-03-07 EP EP05725210A patent/EP1722783A4/en not_active Withdrawn
- 2005-03-07 CN CNA2005800073209A patent/CN1946397A/zh active Pending
- 2005-03-07 CA CA002557648A patent/CA2557648A1/en not_active Abandoned
- 2005-03-07 JP JP2007502988A patent/JP2007527913A/ja active Pending
- 2005-03-07 BR BRPI0508556-0A patent/BRPI0508556A/pt not_active IP Right Cessation
- 2005-03-07 AU AU2005221131A patent/AU2005221131A1/en not_active Abandoned
-
2007
- 2007-12-12 US US11/954,894 patent/US20080090891A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2557648A1 (en) | 2005-09-22 |
| EP1722783A4 (en) | 2009-08-12 |
| US20080090891A1 (en) | 2008-04-17 |
| WO2005086895A3 (en) | 2006-08-17 |
| WO2005086895A2 (en) | 2005-09-22 |
| EP1722783A2 (en) | 2006-11-22 |
| AU2005221131A1 (en) | 2005-09-22 |
| JP2007527913A (ja) | 2007-10-04 |
| US7368467B2 (en) | 2008-05-06 |
| US20050203159A1 (en) | 2005-09-15 |
| CN1946397A (zh) | 2007-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0508556A (pt) | moduladores de canal iÈnico | |
| BRPI0508532A (pt) | moduladores do canal de ìon | |
| BRPI0508537A (pt) | moduladores do canal de ìon | |
| BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
| BRPI0607897A2 (pt) | compostos oxindol e sua utilização como agentes terapêuticos | |
| BRPI0519424A2 (pt) | composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular | |
| BRPI0615097A2 (pt) | agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| BRPI0408026A (pt) | Quinazolinas úteis como moduladores de canais de ìon | |
| BRPI0508594A (pt) | moduladores de canal de ìon | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BRPI0516483A (pt) | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade | |
| EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| BRPI0509207A (pt) | moduladores canabinóides de tetraidro-indazol | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
| EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
| BRPI0721137B8 (pt) | compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos. | |
| EA200901308A1 (ru) | Ингибиторы белка, активирующего 5-липоксигеназу (flap) | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| BRPI0508522A (pt) | moduladores de canal de ìon | |
| BRPI0911469A8 (pt) | Inibidores de gm-csf e il-17 para terapia | |
| BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |